EP2446903A3 - Verfahren, Zusammensetzungen und Kits zur Behandlung von Schmerzen und Juckreiz - Google Patents
Verfahren, Zusammensetzungen und Kits zur Behandlung von Schmerzen und Juckreiz Download PDFInfo
- Publication number
- EP2446903A3 EP2446903A3 EP11007949A EP11007949A EP2446903A3 EP 2446903 A3 EP2446903 A3 EP 2446903A3 EP 11007949 A EP11007949 A EP 11007949A EP 11007949 A EP11007949 A EP 11007949A EP 2446903 A3 EP2446903 A3 EP 2446903A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- channels
- compound
- voltage
- pruritis
- kits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003251 Pruritus Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000004310 Ion Channels Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000929 nociceptor Anatomy 0.000 abstract 2
- 108091008700 nociceptors Proteins 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86012406P | 2006-11-20 | 2006-11-20 | |
US95859407P | 2007-07-06 | 2007-07-06 | |
US99751007P | 2007-10-03 | 2007-10-03 | |
PCT/US2007/024174 WO2008063603A2 (en) | 2006-11-20 | 2007-11-19 | Methods, compositions, and kits for treating pain and pruritis |
EP07862114A EP2101819B1 (de) | 2006-11-20 | 2007-11-19 | Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07862114A Division EP2101819B1 (de) | 2006-11-20 | 2007-11-19 | Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis |
EP07862114.1 Division | 2007-11-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2446903A2 EP2446903A2 (de) | 2012-05-02 |
EP2446903A3 true EP2446903A3 (de) | 2012-11-14 |
EP2446903B1 EP2446903B1 (de) | 2019-10-09 |
Family
ID=39430358
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20110007950 Withdrawn EP2425858A3 (de) | 2006-11-20 | 2007-11-19 | Zusammensetzungen zur Behandlung von Schmerzen und Juckreiz |
EP11007949.8A Active EP2446903B1 (de) | 2006-11-20 | 2007-11-19 | Zusammensetzungen zur Behandlung von Juckreiz |
EP07862114A Active EP2101819B1 (de) | 2006-11-20 | 2007-11-19 | Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20110007950 Withdrawn EP2425858A3 (de) | 2006-11-20 | 2007-11-19 | Zusammensetzungen zur Behandlung von Schmerzen und Juckreiz |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07862114A Active EP2101819B1 (de) | 2006-11-20 | 2007-11-19 | Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis |
Country Status (10)
Country | Link |
---|---|
US (4) | US20100099772A1 (de) |
EP (3) | EP2425858A3 (de) |
JP (4) | JP2010510227A (de) |
KR (2) | KR20090082507A (de) |
CN (1) | CN103933572B (de) |
AU (1) | AU2007322033B2 (de) |
CA (2) | CA3002443A1 (de) |
DK (1) | DK2101819T3 (de) |
ES (1) | ES2402789T3 (de) |
WO (1) | WO2008063603A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010510227A (ja) | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
WO2008095297A1 (en) * | 2007-02-06 | 2008-08-14 | Origin Biomed Inc. | Composition comprising terpene compounds and methods for inhibiting nerve transmission |
DK2229391T3 (da) | 2007-12-19 | 2014-10-13 | Cancer Res Inst Royal | Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse |
WO2009114139A2 (en) * | 2008-03-11 | 2009-09-17 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
WO2009143175A2 (en) * | 2008-05-19 | 2009-11-26 | Children's Medical Center Corporation | Sensory-specific local anesthesia and prolonged duration local anesthesia |
US9415023B2 (en) | 2008-08-13 | 2016-08-16 | Neuroquest Inc. | Compositions comprising terpene compounds for treating negative sensory phenomena |
KR101188945B1 (ko) | 2009-01-29 | 2012-10-08 | 서울대학교산학협력단 | 설포라판 및 이의 유사체를 포함하는 통증치료제 |
US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
WO2011006073A1 (en) * | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
AU2011258634B2 (en) * | 2010-05-25 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiation of human embryonic stem cells and uses thereof |
EP2629610B1 (de) | 2010-07-27 | 2017-09-06 | Flex Pharma, Inc. | Verfahren und zusammensetzungen zur vorbeugung und linderung von muskelkrämpfen und zur erholung von neuromuskulärer reizbarkeit und erschöpfung nach dem training |
KR20200125765A (ko) * | 2011-02-18 | 2020-11-04 | 아사나 바이오사이언시스 엘엘씨 | 아미노인단 화합물 및 통증 치료에서 그것의 용도 |
DK2771320T3 (en) | 2011-10-24 | 2016-10-03 | Endo Pharmaceuticals Inc | Cyclohexylamines |
US10280398B2 (en) | 2011-11-04 | 2019-05-07 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (DA) neurons for engraftment |
JP4979830B1 (ja) * | 2011-11-10 | 2012-07-18 | 重憲 青木 | 無痛注射用外用剤 |
KR101357980B1 (ko) * | 2011-12-07 | 2014-02-05 | 서울대학교산학협력단 | 유제놀을 포함하는 기계적 이질통 치료용 약학적 조성물 |
KR101243430B1 (ko) * | 2012-04-23 | 2013-03-13 | 서울대학교산학협력단 | 설포라판 및 이의 유사체를 포함하는 건강 기능 식품 조성물 |
US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
WO2014124209A1 (en) | 2013-02-08 | 2014-08-14 | General Mills, Inc. | Reduced sodium food products |
PE20160011A1 (es) | 2013-03-15 | 2016-02-10 | Childrens Medical Center | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada |
CA2910394A1 (en) | 2013-04-26 | 2014-10-30 | Memorial Sloan-Kettering Cancer Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
EP2842428B1 (de) * | 2013-08-27 | 2018-08-08 | Symrise AG | Orale Zubereitung |
KR101856589B1 (ko) | 2015-07-30 | 2018-05-10 | (주)에이엔티랩스 | 라모트리진의 피부성 약물 부작용 예측 방법 |
AU2016301282B2 (en) | 2015-08-03 | 2022-03-17 | Children's Medical Center Corporation | Charged ion channel blockers and methods for use |
WO2017199199A1 (en) * | 2016-05-19 | 2017-11-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonist |
US11253493B2 (en) | 2017-01-23 | 2022-02-22 | Cliff-Cartwright Corporation | Compositions and methods affecting exercise performance |
WO2019191200A1 (en) | 2018-03-27 | 2019-10-03 | American Genomics, Llc | Method and formulation for producing anesthesia of internal aspect of eye wall by topical application |
US20210283098A1 (en) * | 2018-07-05 | 2021-09-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and Compositions for Treating Pain and Itch |
MA55320A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation |
JP2022527690A (ja) | 2019-03-11 | 2022-06-03 | ノシオン セラピューティクス,インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
EP3937945A4 (de) | 2019-03-11 | 2023-01-04 | Nocion Therapeutics, Inc. | Geladene ionenkanalblocker und verfahren zur verwendung |
US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US11617727B2 (en) | 2019-04-30 | 2023-04-04 | Bayer Healthcare Llc | Topical analgesic gel compositions |
CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
JP2023515874A (ja) * | 2020-03-04 | 2023-04-14 | ノイキュアズ,インコーポレーテッド | Trpv1調節物質の投与に関連する交感神経興奮を防止するためのqx314の使用 |
JP2023517604A (ja) * | 2020-03-11 | 2023-04-26 | ノシオン セラピューティクス,インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
WO2022081742A1 (en) * | 2020-10-13 | 2022-04-21 | New York Blood Center, Inc. | Compounds for treatment of hemolysis-and inflammasome-associated diseases |
WO2022099284A1 (en) * | 2020-11-05 | 2022-05-12 | Young Biopharma, Llc | Novel capsaicin analogs and uses thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3519631A (en) * | 1965-08-18 | 1970-07-07 | Boehringer Sohn Ingelheim | Quaternary derivatives of 1,2,3,4-tetra-hydro-9-amino-acridine |
US4069309A (en) * | 1972-09-19 | 1978-01-17 | Avon Products, Inc. | Cationic skin substantive sunscreen composition and method |
WO1998024428A1 (en) * | 1996-12-02 | 1998-06-11 | Brigham & Women's Hospital, Inc. | Long-acting local anesthetics |
WO1999011252A2 (en) * | 1997-09-03 | 1999-03-11 | Nortran Pharmaceuticals, Inc. | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain |
WO2001044218A1 (en) * | 1999-12-15 | 2001-06-21 | Ucb Farchim S.A. | Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals |
WO2001045678A2 (de) * | 1999-12-21 | 2001-06-28 | Id Pharma Gmbh | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung |
US6362197B1 (en) * | 1998-06-09 | 2002-03-26 | Cardiome Pharma Corp. | Compositions and method for treatment of cough |
US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
WO2006010587A1 (en) * | 2004-07-24 | 2006-02-02 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US812554A (en) | 1905-11-08 | 1906-02-13 | Hoechst Ag | Alkamin esters of para-aminobenzoic acid. |
US1889645A (en) | 1930-12-22 | 1932-11-29 | Winthrop Chem Co Inc | Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid |
US2441498A (en) | 1943-07-15 | 1948-05-11 | Astra Apotekarnes Kem Fab | Alkyl glycinanilides |
US2689248A (en) | 1950-06-17 | 1954-09-14 | Sterling Drug Inc | Tertiary-aminoalkyl 4-amino-2-alkoxybenzoates and their synth esis |
US2799679A (en) | 1955-04-28 | 1957-07-16 | Bofors Ab | Process of preparing amides of heterocyclic carboxylic acids |
US2955111A (en) | 1957-01-28 | 1960-10-04 | Bofors Ab | Synthesis of n-alkyl-piperidine and n-alkyl-pyrrolidine-alpha-carboxylic acid amides |
US3160662A (en) | 1957-06-26 | 1964-12-08 | Astra Apotekarnes Kem Fab | Lower alkylaminoacyl amide anesthetics |
NL281394A (de) | 1961-07-25 | |||
US3812147A (en) | 1970-12-22 | 1974-05-21 | Astra Pharma Prod | Acylxylidide local anaesthetics |
US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
US3900481A (en) | 1974-04-01 | 1975-08-19 | Riker Laboratories Inc | Derivatives of pyrrolidine and piperidine |
ATE40994T1 (de) | 1983-08-01 | 1989-03-15 | Astra Laekemedel Ab | L-n-n-propylpipekolsaeure-2,6-xylidid und dessen herstellung. |
US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
US5716622A (en) | 1995-01-06 | 1998-02-10 | The Rockefeller University | Functionally active regions of signal transducer and activators of transcription |
US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
SE508357C2 (sv) | 1996-01-02 | 1998-09-28 | Kay Laserow | Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta |
SE9604751D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Ab | New therapy |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US6623040B1 (en) | 1997-09-03 | 2003-09-23 | Recot, Inc. | Method for determining forced choice consumer preferences by hedonic testing |
EP1216243A1 (de) | 1999-10-01 | 2002-06-26 | Advanced Medicine, Inc. | Quinazolinone und analoga und ihre verwendung als lokalanästhetika |
EE200200314A (et) | 1999-12-15 | 2003-08-15 | Ucb Farchim S.A. | Tsüklilised kvaternaarsed ammooniumiühendid |
WO2001083828A1 (en) | 2000-05-04 | 2001-11-08 | Dzgenes, Llc | TGFβ-RII PROMOTER POLYMORPHISMS |
AU7138601A (en) | 2000-06-23 | 2002-01-08 | Mayo Foundation | Methods of treating neutrophil-related diseases with topical anesthetics |
DE10039449A1 (de) * | 2000-08-11 | 2003-07-24 | Id Pharma Gmbh I Ins | Verwendung einer lokalanästhetikumhaltigen Zusammensetzung zur Behandlung von Hyperalgesien |
US6766319B1 (en) | 2000-10-31 | 2004-07-20 | Robert J. Might | Method and apparatus for gathering and evaluating information |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
US20040146590A1 (en) * | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
CA2446060A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
US7585511B2 (en) | 2002-08-02 | 2009-09-08 | Universite Libre De Bruxelles | Apolipoprotein L-I and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma |
US7943166B2 (en) * | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US20040220187A1 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
ES2223277B1 (es) | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | Composicion anestesica para administracion topica. |
US20070149469A1 (en) | 2003-10-02 | 2007-06-28 | Christian Korherr | Medical use of tbk-1 or of inhibitors thereof |
US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
JP4751336B2 (ja) | 2003-12-11 | 2011-08-17 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 細胞増殖性疾患を治療する化合 |
US20070196866A1 (en) * | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
ES2542847T3 (es) * | 2004-06-02 | 2015-08-12 | Neurogesx Inc. | Formulaciones que comprenden capsaicina, un anestésico local y/o un agente antipruriginoso para el tratamiento del dolor |
JP2008513444A (ja) | 2004-09-20 | 2008-05-01 | コラス ファーマ インコーポレイテッド | リドカイン及び他の局所麻酔剤の標的運搬並びに咳そう及び咳の発作の処置のための方法 |
US7947682B2 (en) | 2004-12-29 | 2011-05-24 | University Of Southern California | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents |
EP1824466A4 (de) | 2004-12-16 | 2008-03-05 | Advanced Inhalation Res Inc | Zusammensetzungen und verfahren für lungenleiden |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
CN104278037B (zh) | 2005-10-12 | 2020-09-15 | 艾德拉药物股份有限公司 | 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物 |
TWI468162B (zh) | 2005-12-13 | 2015-01-11 | 英塞特公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶 |
CA2634491A1 (en) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
EP1867338A1 (de) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmazeutische Zusammensetzung enthaltend Apolipoproteine |
JP2010510227A (ja) | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
CN101156851A (zh) | 2007-09-27 | 2008-04-09 | 刘全胜 | 盐酸尼卡地平分散片及其制备方法 |
WO2009114139A2 (en) | 2008-03-11 | 2009-09-17 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2307367B1 (de) | 2008-07-08 | 2014-09-24 | Board of Regents, The University of Texas System | Neue hemmer der proliferation und aktivierung signalübertragender und transkriptionsaktivierender (stat) proteine |
DE102008037682A1 (de) | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
CN101347427A (zh) | 2008-09-22 | 2009-01-21 | 北京理工大学 | 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方 |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
CA2738816A1 (en) | 2008-10-06 | 2010-04-15 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
EP2411019A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid) |
WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
US9023355B2 (en) | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
US9828637B2 (en) | 2010-04-18 | 2017-11-28 | Wake Forest University Health Sciences | Methods of predicting predisposition to or risk of kidney disease |
US20130225578A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
-
2007
- 2007-11-19 JP JP2009537235A patent/JP2010510227A/ja active Pending
- 2007-11-19 EP EP20110007950 patent/EP2425858A3/de not_active Withdrawn
- 2007-11-19 US US12/515,429 patent/US20100099772A1/en not_active Abandoned
- 2007-11-19 EP EP11007949.8A patent/EP2446903B1/de active Active
- 2007-11-19 CA CA3002443A patent/CA3002443A1/en not_active Abandoned
- 2007-11-19 KR KR1020097012908A patent/KR20090082507A/ko active IP Right Grant
- 2007-11-19 ES ES07862114T patent/ES2402789T3/es active Active
- 2007-11-19 EP EP07862114A patent/EP2101819B1/de active Active
- 2007-11-19 AU AU2007322033A patent/AU2007322033B2/en not_active Ceased
- 2007-11-19 CN CN201410034926.2A patent/CN103933572B/zh not_active Expired - Fee Related
- 2007-11-19 DK DK07862114.1T patent/DK2101819T3/da active
- 2007-11-19 WO PCT/US2007/024174 patent/WO2008063603A2/en active Application Filing
- 2007-11-19 CA CA2668652A patent/CA2668652C/en active Active
- 2007-11-19 KR KR1020147017308A patent/KR20140097446A/ko not_active Application Discontinuation
-
2014
- 2014-01-30 JP JP2014015120A patent/JP5926301B2/ja active Active
- 2014-09-25 US US14/496,629 patent/US9603817B2/en active Active
-
2016
- 2016-04-21 JP JP2016085052A patent/JP2016185955A/ja active Pending
-
2017
- 2017-03-27 US US15/470,324 patent/US10179116B2/en active Active
- 2017-08-14 JP JP2017156304A patent/JP2018039788A/ja active Pending
-
2020
- 2020-04-17 US US16/851,349 patent/US20210186906A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3519631A (en) * | 1965-08-18 | 1970-07-07 | Boehringer Sohn Ingelheim | Quaternary derivatives of 1,2,3,4-tetra-hydro-9-amino-acridine |
US4069309A (en) * | 1972-09-19 | 1978-01-17 | Avon Products, Inc. | Cationic skin substantive sunscreen composition and method |
US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
WO1998024428A1 (en) * | 1996-12-02 | 1998-06-11 | Brigham & Women's Hospital, Inc. | Long-acting local anesthetics |
WO1999011252A2 (en) * | 1997-09-03 | 1999-03-11 | Nortran Pharmaceuticals, Inc. | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain |
US6362197B1 (en) * | 1998-06-09 | 2002-03-26 | Cardiome Pharma Corp. | Compositions and method for treatment of cough |
WO2001044218A1 (en) * | 1999-12-15 | 2001-06-21 | Ucb Farchim S.A. | Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals |
WO2001045678A2 (de) * | 1999-12-21 | 2001-06-28 | Id Pharma Gmbh | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung |
WO2006010587A1 (en) * | 2004-07-24 | 2006-02-02 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia |
Non-Patent Citations (7)
Title |
---|
CAHALAN M D ET AL: "Interactions between quaternary lidocaine, the sodium channel gates, and tetrodotoxin.", BIOPHYSICAL JOURNAL JUL 1979, vol. 27, no. 1, July 1979 (1979-07-01), pages 39 - 55, XP002486709, ISSN: 0006-3495 * |
KIRKPATRICK W E ET AL: "Comparison of the effects of procaine, chlorpromazine and their quaternary derivatives on nerve action potentials.", RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY JAN 1970, vol. 1, no. 1, January 1970 (1970-01-01), pages 149 - 155, XP009102648, ISSN: 0034-5164 * |
NIELSEN A B ET AL: "Assessment of the combined approach of N-alkylation and salt formation to enhance aqueous solubility of tertiary amines using bupivacaine as a model drug", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 1, 1 January 2005 (2005-01-01), pages 85 - 93, XP027803616, ISSN: 0928-0987, [retrieved on 20050101] * |
NIELSEN A B ET AL: "Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine-synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 5, 1 April 2005 (2005-04-01), pages 433 - 440, XP027803766, ISSN: 0928-0987, [retrieved on 20050401] * |
OMANA-ZAPATA I ET AL: "QX-314 inhibits ectopic nerve activity associated with neuropathic pain.", BRAIN RESEARCH 17 OCT 1997, vol. 771, no. 2, 17 October 1997 (1997-10-17), pages 228 - 237, XP002486707, ISSN: 0006-8993 * |
RICH T C ET AL: "Quaternary quinidine derivatives as a tool to study: Block of human potassium channels", BIOPHYSICAL JOURNAL, vol. 66, no. 2 PART 2, 1994, & THIRTY-EIGHTH ANNUAL MEETING OF THE BIOPHYSICAL SOCIETY; NEW ORLEANS, LOUISIANA, USA; MARCH 6-10, 1994, pages A143, XP009102646, ISSN: 0006-3495 * |
STRICHARTZ G R: "The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine.", THE JOURNAL OF GENERAL PHYSIOLOGY JUL 1973, vol. 62, no. 1, July 1973 (1973-07-01), pages 37 - 57, XP002486708, ISSN: 0022-1295 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010510227A (ja) | 2010-04-02 |
EP2425858A3 (de) | 2012-03-28 |
CA2668652C (en) | 2018-06-12 |
ES2402789T3 (es) | 2013-05-08 |
JP2018039788A (ja) | 2018-03-15 |
EP2101819B1 (de) | 2013-01-09 |
EP2446903B1 (de) | 2019-10-09 |
US20150087714A1 (en) | 2015-03-26 |
WO2008063603A2 (en) | 2008-05-29 |
US20170319517A1 (en) | 2017-11-09 |
JP5926301B2 (ja) | 2016-05-25 |
CA2668652A1 (en) | 2008-05-29 |
CN103933572A (zh) | 2014-07-23 |
KR20090082507A (ko) | 2009-07-30 |
AU2007322033B2 (en) | 2013-07-11 |
JP2016185955A (ja) | 2016-10-27 |
EP2425858A2 (de) | 2012-03-07 |
JP2014111626A (ja) | 2014-06-19 |
EP2101819A2 (de) | 2009-09-23 |
US20100099772A1 (en) | 2010-04-22 |
US10179116B2 (en) | 2019-01-15 |
AU2007322033A2 (en) | 2009-07-16 |
CN103933572B (zh) | 2017-10-13 |
DK2101819T3 (da) | 2013-04-29 |
WO2008063603A3 (en) | 2008-12-11 |
AU2007322033A1 (en) | 2008-05-29 |
US20210186906A1 (en) | 2021-06-24 |
CA3002443A1 (en) | 2008-05-29 |
US9603817B2 (en) | 2017-03-28 |
EP2446903A2 (de) | 2012-05-02 |
KR20140097446A (ko) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2446903A3 (de) | Verfahren, Zusammensetzungen und Kits zur Behandlung von Schmerzen und Juckreiz | |
WO2008049930A3 (en) | A method for profiling kinase inhibitors | |
MX2010009951A (es) | Metodos, composiciones y kits para tratar dolor y prurito. | |
WO2007130646A3 (en) | Hcv coreceptor and methods of use thereof | |
BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
EA200501724A1 (ru) | Соединения, специфичные к меланокортиновым рецепторам | |
BRPI0906104B8 (pt) | derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto | |
WO2005092066A8 (en) | Imidazole compounds | |
NZ609344A (en) | Method for treatment of diarrhea-predominant irritable bowel syndrome | |
EA200870029A1 (ru) | Способ применения антагонистов il-6 с ингибиторами протеасом | |
TW200716622A (en) | Substituted piperidines | |
AU2009236256A8 (en) | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | |
WO2007028088A3 (en) | Methods for enhancing the dewaterability of sludge with alpha-amylase treatment | |
WO2006078503A3 (en) | Compositions for modulation of parp and methods for screening for same | |
EA200900635A1 (ru) | Антагонисты прогестеронового рецептора | |
EP2101772A4 (de) | Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon | |
WO2007111948A3 (en) | Inhibitors of protein prenyltransferases | |
WO2008156677A3 (en) | Cyclic peptide melanocortin receptor ligands | |
WO2008038127A3 (en) | Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use | |
WO2007005780A3 (en) | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | |
WO2007018671A3 (en) | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins | |
UA101018C2 (ru) | Пирролопиримидинкарбоксамиды | |
NO20072832L (no) | Smertestillende middel | |
WO2008118319A3 (en) | Mineralocorticoid receptor modulators | |
ATE538184T1 (de) | Chromfreie, zinkarme, korrosionshemmende pigmentmischung, verfahren zu ihrer herstellung und ihre verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2101819 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 29/00 20060101ALI20120618BHEP Ipc: A61K 31/085 20060101ALI20120618BHEP Ipc: A61K 31/167 20060101ALI20120618BHEP Ipc: A61K 45/06 20060101AFI20120618BHEP Ipc: A61K 31/165 20060101ALI20120618BHEP |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101AFI20121005BHEP Ipc: A61K 31/165 20060101ALI20121005BHEP Ipc: A61K 31/167 20060101ALI20121005BHEP Ipc: A61P 29/00 20060101ALI20121005BHEP Ipc: A61K 31/085 20060101ALI20121005BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169953 Country of ref document: HK |
|
17P | Request for examination filed |
Effective date: 20130514 |
|
17Q | First examination report despatched |
Effective date: 20160104 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602007059352 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0045060000 Ipc: A61K0031085000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/14 20060101ALI20190410BHEP Ipc: A61K 31/165 20060101ALI20190410BHEP Ipc: A61P 17/04 20060101ALI20190410BHEP Ipc: A61P 29/00 20060101ALI20190410BHEP Ipc: A61K 9/00 20060101ALI20190410BHEP Ipc: A61K 45/06 20060101ALI20190410BHEP Ipc: A61K 31/085 20060101AFI20190410BHEP Ipc: A61K 31/167 20060101ALI20190410BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190520 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2101819 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007059352 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1187972 Country of ref document: AT Kind code of ref document: T Effective date: 20191115 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20191009 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1187972 Country of ref document: AT Kind code of ref document: T Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200210 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200110 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200109 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007059352 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191119 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200209 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
26N | No opposition filed |
Effective date: 20200710 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200603 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191209 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20071119 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230505 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1169953 Country of ref document: HK |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231127 Year of fee payment: 17 |